^
Association details:
| Biomarker: | EGFR L858R + RBM10 2167-1 G>T |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer
Published date:
10/27/2020
Excerpt:
In a fourth clinical case, an EGFR L858R NSCLC harbored a co-occurring RBM10 c2167-1 G>T splice site mutation as detected by clinical-grade NGS. This patient was enrolled in the same neo-adjuvant osimertinib clinical trial and also showed minimal EGFR TKI response, with 68.3% tumor cell viability in the osimertinib-treated...
DOI:
10.1101/2020.10.26.356352
